

Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**
 (Use as many sheets as necessary)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SS/05A(10-01)
 Approved for use through 10/31/2002. OMB 051-0031
 US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE

Complete if Known	
Application Number	Unknown 10/668,057
Filing Date	Even Date Herewith
First Named Inventor	Sandler, Anthony
Group Art Unit	Unknown 1643
Examiner Name	Sisson, Bradley D. Humphrey

Sheet 1 of 2

Attorney Docket No: 875.099US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date if Appropriate
DH	US-6,001,962	12/14/1999	Ramer, J. K., et al.	580	324	11/15/1996
DH	US-6,077,709	06/20/2000	Bennett, C. F., et al.	435	375	09/29/1998
DH	US-6,103,237	08/15/2000	Saedi, M. S., et al.	424	185.1	03/26/1996

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²
---------------------	---------------------	------------------	---	-------	----------	----------------

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DH		ADIDA, C., et al., "Anti-apoptosis gene, survivin, and prognosis of neuroblastoma", <u>The Lancet</u> , 351, (1998), pp. 882-883	
DH		AMBROSINI, G., et al., "A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma", <u>Nature Medicine</u> , 3 (8), (1997), pp. 917-921	
DH		ASHKENAZI, A., et al., "Death Receptors: Signaling and Modulation", <u>Science</u> , 281 (5381), (1998), pp. 1305-1308	
DH		BRESLOW, N., et al., "Epidemiology of Wilms Tumor", <u>Medical and Pediatric Oncology</u> , 21 (3), (1993), pp. 172-181	
DH		BRODEUR, G. M., et al., "Neuroblastoma", In: <u>Principles and Practice of Pediatric Oncology</u> , Chapter 29, (1997), pp. 761-797	
DH		DEVERAUX, QUINN L., et al., "X-Linked IAP is a Direct Inhibitor of Cell-Death Proteases", <u>Nature</u> , 388 (6639), (1997), pp. 300-304	
DH		DONALDSON, S. A., et al., "Expression of Fas/APO-1 by different clinical stages of human neuroblastoma", <u>Proceedings of the American Association for Cancer Research</u> , 40, Abstract No. 1141, (March 1999), p. 171	
DH		LI, F., et al., "Control of apoptosis and mitotic spindle checkpoint by survivin", <u>Nature</u> , 396, (1998), pp. 580-584	
DH		LI, F., et al., "Pleiotropic cell-division defects and apoptosis induced by interference with survivin function", <u>Nature Cell Biology</u> , 1 (8), (1999), pp. 461-466	
DH		LISTON, P., et al., "Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes", <u>Nature</u> , 379, (1996), pp. 349-353	
DH		LOWRY, O. H., et al., "Protein Measurement With The Folin Phenol Reagent", <u>The Journal of Biological Chemistry</u> , 193, (1951), pp. 265-275	
DH		LU, C., et al., "Expression of A Novel Antiapoptosis Gene, Survivin, Correlated with Tumor Cell Apoptosis and p53 Accumulation in Gastric Carcinomas", <u>Cancer Research</u> , 58 (9), (1998), pp. 1808-1812	
DH		MILLER, L. J., et al., "Apoptosis", <u>Science</u> , 281 (5381), (1998), p. 1301	
DH		SANDLER, A., et al., "Survivin in Apoptosis and Solid Tumors of Childhood",	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**
 (Use as many sheets as necessary)

PTO/SD/08A(10-01)
 Approved for use through 10/31/2002, OMB 05-10031
 US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<i>Complete if Known</i>	
Application Number	Unknown
Filing Date	Even Date Herewith
First Named Inventor	Sandler, Anthony
Group Art Unit	Unknown 1643
Examiner Name	Sisson, Bradley D. Humphrey

Sheet 2 of 2

Attorney Docket No: 875.099US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DA		Surgical Forum, 85th Annual Clinical Congress, Volume L, (1999), pp. 571-572	
OH		SARELA, et al., "Expression of the Antiapoptosis Gene, Survivin, Predicts Death from Recurrent Colorectal Carcinoma", <u>Gut</u> , 46, (May, 2000), 645-650	
OH		SWANA, H. S., et al., "Tumor Content of the Antiapoptosis Molecule Survivin and Recurrence of Bladder Cancer", <u>The New England Journal of Medicine</u> , 341 (6), (1999), pp. 452-453	
DA		TAKAMIZAWA, S., et al., "Differential Apoptosis Gene Expression in Pediatric Tumors of the Kidney", <u>Journal of Pediatric Surgery</u> , 35 (2), (Feb. 2000), pp. 390-395	
OH		TAMM, I., et al., "IAP-Family Protein Survivin Inhibits Caspase Activity and Apoptosis Induced by Fas (CD95), Bax, Caspases, and Anticancer Drugs", <u>Cancer Research</u> , 58 (23), (1998), pp. 5315-5320	
OH		THOMPSON, C. B., "Apoptosis in the Pathogenesis and Treatment of Disease", <u>Science</u> , 267, (1995), pp. 1456-1462	

EXAMINER

DATE CONSIDERED

4/10/06

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 806. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO and/or 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

1 of 1

Complete if Known

Application Number	10/668,057
Filing Date	September 22, 2003
First Named Inventor	Sandler
Group Art Unit	1634 1643
Examiner Name	Bradley L. Sisson <i>D. Humphrey</i>

Attorney Docket No: 17023.032US1

US PATENT DOCUMENTS

Examiner Initials *	US Document Number	Publication Date	Name of Patentee/Applicant of Document
<i>DH</i>	6,656,684	12/02/2003	Sandler

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Foreign Document Number (include country code)	Publication Date	Translation (Abstract Only or Full Translation, if applicable)

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Include last name of the first author (in CAPITAL letters), "Title of the Article", "Title of the Source" (book, magazine, journal, serial, symposium, catalog, etc.), "Volume-Number, page(s) and (date).
<i>DH</i>	Azuhata et al., "The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma", <i>J Pediatr Surg.</i> , 36(12), 1785-1791 (2001).
<i>DH</i>	Sandler et al., "The survivin:fas ratio is predictive of recurrent disease in neuroblastoma", <i>J Pediatr Surg.</i> , 37(3), 507-511 (2002).
<i>DH</i>	Takamizawa et al., "The survivin:fas ratio in pediatric renal tumors", <i>J Pediatr Surg.</i> , 36(1), 37-42 (2001).

EXAMINER

DATE CONSIDERED

4/10/06